OneMedNet Signed Multiyear AI Data Agreement
The Minneapolis-based company will supply de-identified clinical data for AI model development.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Does the sale of de-identified patient data to third-party AI companies increase your trust in healthcare?
OneMedNet Corporation has entered a seven-figure multiyear deal to provide clinical real-world data to an AI-enabled precision medicine firm. The agreement leverages the company's iRWD platform to support the training of diagnostic models.
Why it matters
This partnership aims to accelerate the development of AI-driven clinical tools by utilizing vast repositories of patient information. By creating licensable derivative datasets, the companies seek to enhance the accuracy and scope of diagnostic technology.
OneMedNet maintains a network of over 2,300 healthcare partner sites containing 90 million patient journeys and 270 million medical studies. The company expects to increase contract value through planned volume expansions.
The players
OneMedNet Corporation
A Minneapolis-based company that provides real-world clinical data to healthcare organizations and researchers.
The details
OneMedNet utilizes its proprietary iRWD platform to deliver de-identified clinical information from its extensive healthcare network. The partnership allows for the creation of new derivative datasets that the customer will use for training advanced diagnostic and clinical models.
Timeline
September 30, 2026: OneMedNet announced the multiyear agreement.
Market Landscape
This deal underscores the ongoing industry push to monetize vast patient datasets through AI-enabled precision medicine partnerships. OneMedNet continues to strengthen its competitive position by expanding the reach of its iRWD platform and data infrastructure.
While this agreement focuses on corporate data licensing, patients within the OneMedNet network benefit from the assurance that all shared information is de-identified at the source. The partnership does not change individual service costs or personal healthcare access for residents.
The takeaway
This deal highlights how clinical data has become a critical asset for the advancement of machine learning in diagnostic medicine. It demonstrates the growing value of aggregated, de-identified patient journeys in training complex AI models for future clinical applications.
Further reading
For additional context on the local medical technology sector, visit Minneapolis Healthcare.
More information
Find more details on the company's data practices on the OneMedNet company information page.
Live Poll
Does the sale of de-identified patient data to third-party AI companies increase your trust in healthcare?
